Provided by Tiger Fintech (Singapore) Pte. Ltd.

Insmed

76.29
-1.7000-2.18%
Post-market: 76.290.00000.00%19:46 EDT
Volume:2.94M
Turnover:223.18M
Market Cap:13.81B
PE:-13.70
High:76.70
Open:76.24
Low:73.81
Close:77.99
Loading ...

Company Profile

Company Name:
Insmed
Exchange:
NASDAQ
Establishment Date:
1988
Employees:
1271
Office Location:
700 US Highway 202/206,Bridgewater,New Jersey,United States
Zip Code:
08807
Fax:
- -
Introduction:
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Directors

Name
Position
Donald J. Hayden, Jr.
Non-Executive Chairman of Board
William H. Lewis
Director, President and Chief Executive Officer
Alfred Altomari
Director
David R. Brennan
Director
David W. J. McGirr
Director
Melvin Sharoky
Director
Myrtle Potter
Director
Steinar J. Engelsen
Director

Shareholders

Name
Position
William H. Lewis
Director, President and Chief Executive Officer
Paolo Tombesi
Chief Financial Officer
Christine Pellizzari
Chief Legal Officer
Paul Streck
Chief Medical Officer
Roger Adsett
Chief Commercial Officer